Washington, D.C. (November 24, 2025) – UsAgainstAlzheimer’s released the following statement after Novo Nordisk announced results from its phase 3 EVOKE and EVOKE+ trials today: 

“Today’s news is disappointing, because people living with Alzheimer’s and their families need and deserve more treatment options. These initial findings reinforce the urgent need to accelerate other rigorous, long-term trials that can deliver choices and hope to the individuals and families facing this disease.  We will be watching closely for the full EVOKE and EVOKE+ results when they are released. 

“In the meantime, UsAgainstAlzheimer’s will continue to push for swift progress so that individuals facing this difficult diagnosis have choices and that we are able to unlock new pathways for treatment and risk reduction.  We remain encouraged that many other potential Alzheimer’s drugs are still in development for this devastating disease.”

# # #

About UsAgainstAlzheimer’s


UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.